BioNTech vs Zimmer Biomet Holdings
BioNTech (BNTX), health care, and Zimmer Biomet Holdings (ZBH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
BioNTech is worth $21B on the stock market and Zimmer Biomet Holdings $19.3B: BioNTech is valued at 9% more. BioNTech's operating margin in its latest fiscal year was -49.0% and Zimmer Biomet Holdings's 13.3%. Over the past year BioNTech's share price has moved -16.8% and Zimmer Biomet Holdings's +13.8%.
Key facts
- BioNTech market value
- $21B
- Zimmer Biomet Holdings market value
- $19.3B
- Zimmer Biomet Holdings P/E
- 25.6
- BioNTech revenue
- $3.2BFY to 2025-12-31
- Zimmer Biomet Holdings revenue
- $8.2BFY to 2025-12-31
- Superinvestors holding both
- 2
Market values as of .
| Measure | BioNTech | Zimmer Biomet Holdings |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $21Bhigher | $19.3Blower |
| Revenue | $3.2Blower | $8.2Bhigher |
| Earnings | -$1.3Blower | $705.1Mhigher |
| Employees | 7,807lower | 17,000higher |
| Total assets | $24.4Bhigher | $23.1Blower |
| Valuation | ||
| P/E | — | 25.6 |
| P/S | 6.6higher | 2.3lower |
| P/B | — | 1.5 |
| Dividend yield | — | 0.95% |
| Profitability | ||
| Operating margin | -49.0%lower | 13.3%higher |
| Balance sheet | ||
| Net assets | $21.3Bhigher | $12.7Blower |
| Total liabilities | $3.1Blower | $10.4Bhigher |
| Total debt | — | $7.5B |
| Cash on hand | $8.5Bhigher | $591.9Mlower |
| Price change | ||
| Today | -0.47%lower | +0.67%higher |
| 1 year | -16.8%lower | +13.8%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (2)
- Primecap team0.2% / 0.2%
- Dodge & Cox team0.2% / 1.1%
BioNTech only (2)
- Temasek0.3%
- Julian and Felix Baker0.1%
Zimmer Biomet Holdings only (8)
- Harry Burn2.2%
- Bill Nygren1.5%
- Sarah Ketterer0.4%
- Louis Bacon0.3%
- Brandon Haley0.2%
- Mario Gabelli0.2%
- Ken Griffin0.2%
- Charles Brandes (founder)0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": BioNTech / Zimmer Biomet Holdings). Who owns BNTX · Who owns ZBH
More on BioNTech
Further comparisons
BioNTech against its closest peers
Zimmer Biomet Holdings against its closest peers
Learn
Questions and answers
Which is bigger, BioNTech or Zimmer Biomet Holdings?
By market value, BioNTech is the larger: $21B against $19.3B for Zimmer Biomet Holdings. By revenue in its latest fiscal year, Zimmer Biomet Holdings is the larger: $8.2B against $3.2B for BioNTech.
Which has the higher operating margin?
Zimmer Biomet Holdings: 13.3%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both BioNTech and Zimmer Biomet Holdings?
In their latest 13F filings, Primecap team and Dodge & Cox team hold both.
Cite this page
Funkfolio, “BioNTech vs Zimmer Biomet Holdings”, data as of 18 November 2026. https://funkfolio.com/compare/bntx-vs-zbh
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.